Nan Wu

机构：Tung Wah College, City University of Hong Kong, First Affiliated Hospital of Xi'an Jiaotong University, Affiliated Hospital of Jining Medical University, Jinzhou Medical University · ORCID：0000-0002-9939-9810

发表论文 115 篇 · 总被引 3773 次 · h-index 36

代表论文

• Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial (2023 · Lung Cancer · 被引 115)
• TGF‐β/Smads signaling pathway, Hippo‐YAP/TAZ signaling pathway, and VEGF: Their mechanisms and roles in vascular remodeling related diseases (2023 · Immunity Inflammation and Disease · 被引 58)
• Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study) (2023 · ESMO Open · 被引 27)
• TAF15 exacerbates nonalcoholic steatohepatitis progression by regulating lipid metabolism and inflammation via FASN and p65 NF‐κB (2023 · Liver International · 被引 20)
• Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis (2023 · BMC Cancer · 被引 16)
• Chrom-seq identifies RNAs at chromatin marks (2024 · Science Advances · 被引 12)